Literature DB >> 10903528

PTEN, a unique tumor suppressor gene.

P L Dahia1.   

Abstract

For many years, it has been thought that the chromosome region 10q22-24 includes one or more genes that appear to play a role in several human malignancies. PTEN is a new tumor suppressor gene encoding a dual-specificity phosphatase that was cloned simultaneously by three groups (Li & Sun 1997, Li et al. 1997, Steck et al. 1997), two of which used a positional cloning approach to identify genes in chromosome 10 (Li et al. 1997, Steck et al. 1997). While several protein kinases have been implicated as oncogenes, and phosphatases have long been known frequently to antagonize their function, there has been no direct demonstration of the role of phosphatases in tumor development (Myers & Tonks 1997). PTEN characterization as a bona fide tumor suppressor gene has confirmed that a deficient phosphatase activity can lead to cancer, as detailed by studies that are described below.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10903528     DOI: 10.1677/erc.0.0070115

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  85 in total

Review 1.  Pulling strings below the surface: hormone receptor signaling through inhibition of protein tyrosine phosphatases.

Authors:  X Espanel; S Wälchli; R P Gobert; M El Alama; M L Curchod; N Gullu-Isler; R Hooft van Huijsduijnen
Journal:  Endocrine       Date:  2001-06       Impact factor: 3.633

2.  HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer.

Authors:  Imran Ahmad; Rachana Patel; Lukram Babloo Singh; Colin Nixon; Morag Seywright; Robert J Barnetson; Valerie G Brunton; William J Muller; Joanne Edwards; Owen J Sansom; Hing Y Leung
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

3.  Loss of PTEN permits CXCR4-mediated tumorigenesis through ERK1/2 in prostate cancer cells.

Authors:  Mahandranauth A Chetram; Valerie Odero-Marah; Cimona V Hinton
Journal:  Mol Cancer Res       Date:  2010-11-12       Impact factor: 5.852

4.  SLUG is a direct transcriptional repressor of PTEN tumor suppressor.

Authors:  Berna Uygur; Katrina Abramo; Evgenia Leikina; Calvin Vary; Lucy Liaw; Wen-Shu Wu
Journal:  Prostate       Date:  2015-03-01       Impact factor: 4.104

5.  Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions.

Authors:  N R Leslie; D Bennett; A Gray; I Pass; K Hoang-Xuan; C P Downes
Journal:  Biochem J       Date:  2001-07-15       Impact factor: 3.857

Review 6.  Targeting the PI3-kinase/Akt/mTOR signaling pathway.

Authors:  Burhan Hassan; Argun Akcakanat; Ashley M Holder; Funda Meric-Bernstam
Journal:  Surg Oncol Clin N Am       Date:  2013-08-06       Impact factor: 3.495

7.  Targeted polyubiquitylation of RASSF1C by the Mule and SCFβ-TrCP ligases in response to DNA damage.

Authors:  Xin Zhou; Ting-Ting Li; Xu Feng; Esther Hsiang; Yue Xiong; Kun-Liang Guan; Qun-Ying Lei
Journal:  Biochem J       Date:  2012-01-01       Impact factor: 3.857

Review 8.  Inhibiting PI3K as a therapeutic strategy against cancer.

Authors:  Luis Paz-Ares; Carmen Blanco-Aparicio; Rocío García-Carbonero; Amancio Carnero
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

9.  Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis.

Authors:  Nathalie Dourdin; Babette Schade; Robert Lesurf; Michael Hallett; Robert J Munn; Robert D Cardiff; William J Muller
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

10.  Inactivation of the tumour suppressor, PTEN, in smooth muscle promotes a pro-inflammatory phenotype and enhances neointima formation.

Authors:  Seth B Furgeson; Peter A Simpson; Insun Park; Vicki Vanputten; Henrick Horita; Christopher D Kontos; Raphael A Nemenoff; Mary C M Weiser-Evans
Journal:  Cardiovasc Res       Date:  2010-01-05       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.